Compare MSBI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | PRTC |
|---|---|---|
| Founded | 1881 | 2015 |
| Country | United States | United States |
| Employees | 861 | 90 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.7M | 400.2M |
| IPO Year | N/A | N/A |
| Metric | MSBI | PRTC |
|---|---|---|
| Price | $23.61 | $18.00 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $22.83 | N/A |
| AVG Volume (30 Days) | ★ 117.7K | 3.3K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.24 | $14.50 |
| 52 Week High | $24.72 | $19.92 |
| Indicator | MSBI | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 60.31 | 69.02 |
| Support Level | $20.81 | $18.07 |
| Resistance Level | $24.41 | $19.49 |
| Average True Range (ATR) | 0.58 | 0.49 |
| MACD | 0.15 | 0.39 |
| Stochastic Oscillator | 65.40 | 95.67 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.